RxActuator secures seed funding to relaunch wearable pet infusion device

Veteran-led RxActuator has raised seed investment from Waypoint Ventures to scale its Mini-Infuser, a wearable continuous-rate infusion device for animals. The funding will support manufacturing, clinic adoption and a broader push to let stable pets recover at home after treatment.

Why it matters: - The Mini-Infuser is designed to move some veterinary infusion care out of the hospital and into the home. - That shift can reduce stress for stable pets and their families while lowering treatment costs. - Published research cited by RxActuator found outpatient continuous infusion had an 89.5% success rate and cost about 60% to 70% less than inpatient care.

What happened: - Journey Actuating Technologies, Inc., doing business as RxActuator, announced a seed investment from Waypoint Ventures on October 15, 2026. - The investment anchors RxActuator's seed round. - The funding supports the commercial relaunch of the Mini-Infuser, a patented, wearable, non-powered continuous-rate infusion device for animals. - RxActuator relaunched the product on October 1, 2026. - The company is based in Raleigh, North Carolina, and is veteran-owned.

The details: - The Mini-Infuser delivers medication subcutaneously for 48 hours. - Veterinarians use the device after surgery, for chronic pain, hospice and palliative care, antibiotics and other cases that require continuous medication delivery. - Continuous-rate infusion is common in veterinary hospitals, but traditional setups usually keep patients tethered to an IV pump. - Journey Actuating Technologies acquired the Mini-Infuser technology and related assets in early 2026. - More than 500 units have been used by more than 90 veterinary clinics in three countries. - Most of that volume has come from repeat accounts. - A 2025 study in the Journal of Veterinary Internal Medicine by Erger et al. reported the outpatient infusion results. - More information is available through RxActuator's LinkedIn page.

Between the lines: - Waypoint Ventures is backing a company that says the device and market need are already proven. - RxActuator is framing the Mini-Infuser as a practical alternative to clinic-based infusion care, not a speculative product concept. - The company's pitch blends animal care, lower costs and operational simplicity for veterinary teams. - Founder and CEO Jeff Journey is a U.S. Air Force veteran, and Waypoint is emphasizing mission-driven execution as part of the investment thesis.

What's next: - RxActuator will use the capital to scale commercial operations and veterinary clinic adoption. - The company also plans to expand manufacturing capacity and margins. - RxActuator plans to broaden clinical protocols into new specialties. - The company intends to develop intelligent infusion technology that links drug delivery to real-world clinical outcomes.

The bottom line: - RxActuator is using new capital to turn a niche veterinary device into a broader at-home treatment platform for stable animals.